8-K: Clene Inc. Announces Positive Long-Term Data for CNM-Au8 in ALS Treatment

Clene Inc. presented new data showing improved survival and reduced neurofilament light levels in ALS patients treated with CNM-Au8 in an open label extension of the HEALEY ALS Platform Trial.

Summary

• Clene Inc. presented data at the 2024 ENCALS Meeting regarding their drug CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS).
• The data comes from the open label extension (OLE) of the HEALEY ALS Platform Trial.
• The results show that patients treated with CNM-Au8 30 mg had improved survival up to 3.5 years compared to matched controls.
• Specifically, there was an approximate 60% decreased risk of death in the CNM-Au8 treated group.
• The study also showed a 28% average reduction in neurofilament light (NfL) levels in a subset of patients, suggesting decreased axonal loss.
• The treatment was well-tolerated with over 650 patient years of exposure without any identified safety signals.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data with significant improvements in survival and biomarker levels, suggesting a promising treatment for ALS. The lack of safety concerns further boosts the positive sentiment.

Positives

• The study demonstrated a significant improvement in survival for ALS patients treated with CNM-Au8.
• The reduction in NfL levels suggests a positive impact on axonal health.
• The treatment was shown to be safe and well-tolerated over a long period.
• The data provides further evidence to support CNM-Au8 as a potential treatment for ALS.

Risks

• The company's ability to demonstrate the efficacy and safety of their drug candidates is crucial for further development.
• Clinical results may not always support further development or marketing approval.
• Regulatory agencies can affect the initiation, timing, and progress of clinical trials and marketing approval.
• The company's ability to achieve commercial success for their drug candidates, if approved, is not guaranteed.
• The company has a limited operating history and relies on obtaining additional funding for operations.

Future Outlook

The company is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ALS, Parkinson's disease, and multiple sclerosis. They will continue to develop and seek approval for CNM-Au8.

Management Comments

• Benjamin Greenberg, M.D., Head of Medical at Clene, stated that the clinical evidence of plasma neurofilament reduction, as well as the long-term improved survival results, provides further evidence to strongly support CNM-Au8 as a potential treatment for ALS.

Industry Context

This announcement is significant in the context of the ongoing search for effective treatments for ALS, a devastating neurodegenerative disease. The positive survival and biomarker data for CNM-Au8 could position it as a promising therapy in a field with limited treatment options.

Comparison to Industry Standards

• The survival data is compared to a matched PRO-ACT control group, which is a large multi-study ALS dataset of more than 12,000 patients across multiple clinical centers, providing a robust benchmark.
• The hazard ratio of 0.431 for survival is a significant improvement compared to typical outcomes in ALS, where disease progression is usually rapid and survival is limited.
• The 28% reduction in NfL levels is also a notable result, as NfL is a well-established biomarker for axonal damage in neurodegenerative diseases, and reductions are indicative of a positive treatment effect.
• Other companies developing ALS treatments include Biogen with Tofersen and Amylyx Pharmaceuticals with Relyvrio, but the specific mechanisms and results of CNM-Au8 are unique and warrant further investigation.

Stakeholder Impact

• Shareholders may react positively to the promising clinical data.
• Patients with ALS and their families may have increased hope for a new treatment option.
• Employees of Clene may be motivated by the positive results.
• The medical community may be interested in further research and development of CNM-Au8.

Next Steps

• The company will continue to develop and seek regulatory approval for CNM-Au8.
• The poster presentation is available on the Clene website.

Key Dates

Keywords

CNM-Au8, ALS, Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Neurofilament Light, Survival, HEALEY ALS Platform Trial, Clinical Trial, Biomarker, Mitochondrial Health